Dnx Biopharmaceuticals

DNX is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products. DNX aims to develop its lead product (DNX-114) as the first, 2nd generation long-acting, high-affinity soluble TNF receptor antagonist using PASylation, for the treatment of rheumatoid arthritis and other related diseases, while off-setting the development cost through corporate deals involving company-specific target drug selection (e.g. DNX-214|314|414|514) for half-life modification and for favorably prolonging the long-term fade-rates of those product franchises.